Literature DB >> 11049808

Progressive multifocal leukoencephalopathy and idiopathic CD4+lymphocytopenia: a case report and review of reported cases.

S Haider1, D Nafziger, J A Gutierrez, I Brar, N Mateo, J Fogle.   

Abstract

Progressive multifocal leukoencephalopathy (PML) is a well recognized demyelinating neurological disorder caused by JC virus. Idiopathic CD4(+) lymphocytopenia (ICL) is a syndrome first described by the Centers for Disease Control and Prevention as a CD4(+) count <300 cells/mm(3) or a CD4(+) count that is <20% of the total T cell count on 2 occasions, with no evidence of human immunodeficiency virus (HIV) infection on testing, and absence of any defined immunodeficiency or therapy that depresses the levels of CD4(+) T cells. To the best of our knowledge, this is the third reported case of PML and ICL, and also the first reported case of the use of cidofovir to treat PML in a patient not infected with human immunodeficiency virus.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11049808     DOI: 10.1086/318120

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  22 in total

1.  Fatal varicella zoster virus infection as first manifestation of idiopathic CD4+ T-cell lymphocytopenia.

Authors:  K Hochauf; D Bandt; C Pöhlmann; S Monecke; M Toma; S Trautmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-10       Impact factor: 3.267

2.  JC virus infection of the brain.

Authors:  A K Bag; J K Curé; P R Chapman; G H Roberson; R Shah
Journal:  AJNR Am J Neuroradiol       Date:  2010-03-18       Impact factor: 3.825

3.  Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression.

Authors:  Jessie Grewal; Poorvi Dalal; Michelle Bowman; Behiye Kaya; José Javier Otero; Jaime Imitola
Journal:  J Neurovirol       Date:  2016-06-06       Impact factor: 2.643

4.  Progressive Multifocal Leukoencephalopathy in Primary Immunodeficiencies.

Authors:  Jérôme Hadjadj; Aurélien Guffroy; Christophe Delavaud; Guillaume Taieb; Isabelle Meyts; Anne Fresard; Nathalie Streichenberger; Anne-Sophie L'Honneur; Flore Rozenberg; Maud D'Aveni; Claire Aguilar; Jérémie Rosain; Capucine Picard; Nizar Mahlaoui; Marc Lecuit; Olivier Hermine; Olivier Lortholary; Felipe Suarez
Journal:  J Clin Immunol       Date:  2018-12-14       Impact factor: 8.317

Review 5.  Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain.

Authors:  Michael W Ferenczy; Leslie J Marshall; Christian D S Nelson; Walter J Atwood; Avindra Nath; Kamel Khalili; Eugene O Major
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

Review 6.  Identification of a novel mutation in MAGT1 and progressive multifocal leucoencephalopathy in a 58-year-old man with XMEN disease.

Authors:  Fatima Dhalla; Sarah Murray; Ross Sadler; Benjamin Chaigne-Delalande; Tomohiko Sadaoka; Elizabeth Soilleux; Gulbu Uzel; Joanne Miller; Graham Peter Collins; Christian Simon Ross Hatton; Malini Bhole; Berne Ferry; Helen M Chapel; Jeffrey I Cohen; Smita Y Patel
Journal:  J Clin Immunol       Date:  2014-12-13       Impact factor: 8.317

Review 7.  Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.

Authors:  Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

Review 8.  Immune surveillance and response to JC virus infection and PML.

Authors:  Sarah Beltrami; Jennifer Gordon
Journal:  J Neurovirol       Date:  2013-12-03       Impact factor: 2.643

9.  False negative PCR despite high levels of JC virus DNA in spinal fluid: Implications for diagnostic testing.

Authors:  Marie L Landry; Tore Eid; Serguei Bannykh; Eugene Major
Journal:  J Clin Virol       Date:  2008-08-12       Impact factor: 3.168

Review 10.  Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients.

Authors:  Elizabeth A Mills; Yang Mao-Draayer
Journal:  Mult Scler       Date:  2018-05-18       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.